Quince Therapeutics announces Phase 3 ATTeST trial for A-T evaluated in Lancet

Quince Therapeutics announced the online publication of data in The Lancet Neurology from its Phase 3 ATTeST or Ataxia-Telangiectasia Trial with the EryDex SysTem clinical trial evaluating the safety and efficacy of its lead asset, EryDex or dexamethasone sodium phosphate encapsulated in autologous erythrocytes , for the treatment of A-T. “The results of this study demonstrate the encouraging efficacy and safety profile of our lead asset, EryDex, for the treatment of patients with A-T, a rare pediatric disease with vast unmet need and no approved treatments,” said Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer. “These findings provide us with additional confidence in our pivotal Phase 3 study of EryDex now underway with a primary analysis population comprised of patients with A-T experiencing the most rapid clinical decline – children ages six to nine – in addition to including participants who are ten years of age or older.”